Why AstraZeneca is on investors’ radar today AstraZeneca (LSE:AZN) has drawn attention after a period of solid recent share performance, with returns over the past month and past 3 months standing out ...

The COVID-19 vaccine participant whose unexpected illness put the AstraZeneca trials on pause came down with an inflammatory syndrome known as transverse myelitis, according to a report. The ...

If you are wondering whether AstraZeneca's share price still offers value or is starting to look expensive, the next sections will walk through what the current market price might be implying.

British drugmaker AstraZeneca (AZN), fresh off a record-high stock price, continues to draw interest from U.S. and European investors thanks to, among others, its plan to start trading directly in New ...

AstraZeneca AZN is scheduled to report fourth-quarter and full-year 2025 results on Feb. 10, before the opening bell. In the last reported quarter, the company delivered an earnings surprise of 4.39% ...

AstraZeneca, the U.K.-Swedish pharmaceutical giant, on Tuesday announced a plan to invest some $50 billion in the U.S. in a move hailed by the Trump administration - though much of what it is ...

AstraZeneca PLC is a leading global pharmaceutical company with strong growth in oncology, diversified revenues, and a robust pipeline. AZN's financials show improving margins, rising EPS, and ...

LONDON - AstraZeneca’s COVID-19 vaccine provided strong protection against disease and complete protection against hospitalization and death across all age groups in a late-stage U.S. study, the ...

Astrazeneca boss Pascal Soriot was handed his largest ever pay package last year - taking his total earnings at the pharma ...

Add Yahoo as a preferred source to see more of our stories on Google. A U.S. flag stands next to the AstraZeneca logo in Washington, D.C. By Maggie Fick LONDON (Reuters) -AstraZeneca said on Friday it ...